Compare Abercrombie & Fitch Co. (ANF) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs TG Therapeutics Inc — how do they compare? Abercrombie & Fitch Co. trades at $92.18 (market cap $4.14B), while TG Therapeutics Inc trades at $55.59 (market cap $8.74B). The key difference: TG Therapeutics Inc is far larger — about 2.1× Abercrombie & Fitch Co.'s market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.
| ANF | TGTX | |
|---|---|---|
Market Cap | $4.14B | $8.74B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $59.06 |
52-Week Low | $65.61 | $26.39 |
Enterprise Value | $4.81B | $8.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abercrombie & Fitch (ANF) trades at $93.07, up 4.29% with strong fundamental metrics including a P/E of 9 and net income margin of 9.34%. The stock shows consistent earnings beats in recent quarters and maintains robust profitability with ROE at 39.04%. Technical indicators are neutral overall, with bullish moving averages and key resistance at $94. Recent expansion initiatives include APAC growth opportunities and partnerships with Target for back-to-college merchandise.
ANF presents a compelling value opportunity with attractive valuation multiples and strong operational performance. Upside potential exists to the $107.71 consensus price target, though risks include moderating sales growth and international market volatility. The company's disciplined expansion and brand revitalization support long-term growth prospects.
TG Therapeutics (TGTX) trades at $57.12, down 3.28% on the day, amid mixed technical signals. The stock exhibits strong profitability with a net income margin of 65.95% and robust revenue growth, reaching $616.29 million in 2025. Recent positive news includes the initiation of a Phase II trial for Briumvi in schizophrenia and strong sales momentum, though recent quarterly EPS results have missed expectations. The technical outlook is bullish based on moving averages, but oscillators show bearish pressure with RSI levels indicating potential overbought conditions.
The investment outlook for TGTX is supported by strong analyst sentiment with 84.62% buy ratings and a consensus price target of $45.00, though the current price exceeds this target. Key opportunities include pipeline expansion and rising Briumvi demand, but risks involve clinical trial outcomes, competitive pressures, and cash flow volatility. Investors should weigh the high valuation multiples against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
